Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancer
Crossref DOI link: https://doi.org/10.1007/s00262-015-1706-4
Published Online: 2015-05-09
Published Print: 2015-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Balint, Joseph P.
Gabitzsch, Elizabeth S.
Rice, Adrian
Latchman, Yvette
Xu, Younong
Messerschmidt, Gerald L.
Chaudhry, Arvind
Morse, Michael A.
Jones, Frank R.
Text and Data Mining valid from 2015-05-09